Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 9—September 2012

CME ACTIVITY

Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Allen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas GottliebComments to Author 
Author affiliations: Monash University, Melbourne, Victoria, Australia (A.C. Cheng); Alfred Hospital, Melbourne (A.C. Cheng); Women’s and Children’s Hospital, Adelaide, South Australia, Australia (J. Turnidge); University of Adelaide, Adelaide (J. Turnidge); The Canberra Hospital, Garran, Canberra, Australia (P. Collignon); Australian National University, Canberra (P. Collignon); Princess Alexandra Hospital, Brisbane, Queensland, Australia (D. Looke); University of Queensland, Brisbane (D. Looke); University of South Australia, Adelaide (M. Barton); Concord Hospital, Sydney, New South Wales, Australia (T. Gottlieb); and University of Sydney, Sydney (T. Gottlieb)

Main Article

Table 1

Quinolone antimicrobial drugs available for use in humans in Australia under the authority of the PBS*

Drug/route of administration PBS listed indication Consumer cost in AU$
Generic available
Private market† PBS GB PBS CB
Ciprofloxacin

Oral

Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients 25.20 34.20 5.60 Yes
Bacterial gastroenteritis in severely immunocompromised patients
Infections proven to be caused by P. aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobial drugs
Joint and bone infections, epididymo-orchitis, prostatitis, or perichondritis of the pinna suspected or proven to be caused by gram-negative or -positive bacteria resistant to all other appropriate antimicrobial drugs
Gonorrhea

Topical, ear

Treatment of chronic suppurative otitis media in Aborigines or Torres Strait Islanders >1 mo of age 24.51 19.38 5.60 No
Treatment of chronic suppurative otitis media in a patient <18 y of age with perforation of the tympanic membrane
Treatment of chronic suppurative otitis media in a patient <18 y of age with a grommet in situ

Topical, eye

Bacterial keratitis 33.71 28.58 5.60 No
Ofloxacin

Topical, eye

Bacterial keratitis 35.40 32.24 5.60 No
Norfloxacin

Oral

Acute bacterial enterocolitis; complicated urinary tract infection 31.68 17.16 5.60 Yes
Moxifloxacin‡

Oral

No longer listed 70.65 NA NA No

*PBS, Pharmaceutical Benefits Scheme; GB, general beneficiaries; CB, concessional beneficiaries, including pensioners; NA, no longer available in PBS.
†Price to consumer varies between retail outlets.
‡Data from 2011.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO